Spdr Sp Biotech Etf Performance
| XBI Etf | USD 83.94 0.75 0.89% |
The entity has a beta of 0.33, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, SPDR SP's returns are expected to increase less than the market. However, during the bear market, the loss of holding SPDR SP is expected to be smaller as well.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SPDR SP Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental drivers, SPDR SP is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
1 | SPDR SP Biotech ETF Shares Purchased by Staley Capital Advisers Inc. | 02/27/2024 |
2 | SPDR SP Biotech ETF Stock Holdings Trimmed by Toronto Dominion Bank | 03/05/2024 |
3 | Morgan Stanley Has 537.35 Million Position in SPDR SP Biotech ETF | 03/11/2024 |
4 | United Therapeutics Robust Portfolio Fuels Double-Digit Growth | 03/20/2024 |
5 | AskSlim Market Week - Friday, March 28 | 03/28/2024 |
6 | Zacks Investment Ideas feature highlights SPDR SP Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals | 04/01/2024 |
7 | Parsons Capital Management Inc. RI Makes New 237000 Investment in SPDR SP Biotech ETF - Defense World | 04/04/2024 |
8 | SPDR SP Biotech ETF Shares Acquired by Prime Capital Investment Advisors LLC - Defense World | 04/11/2024 |
9 | Novo Nordisk Growth Is Still A Better Choice | 04/22/2024 |
| In Threey Sharp Ratio | -0.40 |
SPDR |
SPDR SP Relative Risk vs. Return Landscape
If you would invest 8,824 in SPDR SP Biotech on January 26, 2024 and sell it today you would lose (430.00) from holding SPDR SP Biotech or give up 4.87% of portfolio value over 90 days. SPDR SP Biotech is generating negative expected returns assuming volatility of 1.8785% on return distribution over 90 days investment horizon. In other words, 16% of etfs are less volatile than SPDR, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
SPDR SP Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SPDR SP's investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as SPDR SP Biotech, and traders can use it to determine the average amount a SPDR SP's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.033
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XBI |
Estimated Market Risk
| 1.88 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SPDR SP is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SPDR SP by adding SPDR SP to a well-diversified portfolio.
SPDR SP Fundamentals Growth
SPDR Etf prices reflect investors' perceptions of the future prospects and financial health of SPDR SP, and SPDR SP fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SPDR Etf performance.
| Price To Earning | 19.71 X | |||
| Price To Book | 2.64 X | |||
| Price To Sales | 7.52 X | |||
| Total Asset | 7.34 B | |||
About SPDR SP Performance
To evaluate SPDR SP Biotech Etf as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when SPDR SP generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare SPDR Etf's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand SPDR SP Biotech market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents SPDR's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.In seeking to track the performance of the SP Biotechnology Select Industry Index , the fund employs a sampling strategy. SP Biotech is traded on NYSEARCA Exchange in the United States.| SPDR SP Biotech generated a negative expected return over the last 90 days | |
| Latest headline from gurufocus.com: Novo Nordisk Growth Is Still A Better Choice | |
| This fund generated-4.0 ten year return of -4.0% | |
| SPDR SP keeps 99.97% of its net assets in stocks |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SPDR SP Biotech. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the SPDR SP Biotech information on this page should be used as a complementary analysis to other SPDR SP's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
The market value of SPDR SP Biotech is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.